X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 20.8 33.7 61.9% View Chart
P/BV x 3.9 2.9 133.3% View Chart
Dividend Yield % 0.3 0.6 55.4%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
CIPLA
Mar-18
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs809663 122.0%   
Low Rs504479 105.2%   
Sales per share (Unadj.) Rs281.1189.0 148.7%  
Earnings per share (Unadj.) Rs41.417.6 235.0%  
Cash flow per share (Unadj.) Rs50.934.0 149.5%  
Dividends per share (Unadj.) Rs2.503.00 83.3%  
Dividend yield (eoy) %0.40.5 72.5%  
Book value per share (Unadj.) Rs199.4176.7 112.8%  
Shares outstanding (eoy) m585.88805.12 72.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.33.0 77.3%   
Avg P/E ratio x15.932.5 48.9%  
P/CF ratio (eoy) x12.916.8 76.9%  
Price / Book Value ratio x3.33.2 101.9%  
Dividend payout %6.017.1 35.5%   
Avg Mkt Cap Rs m384,630459,724 83.7%   
No. of employees `00017.323.6 73.4%   
Total wages/salary Rs m21,30826,901 79.2%   
Avg. sales/employee Rs Th9,500.76,446.1 147.4%   
Avg. wages/employee Rs Th1,229.41,139.4 107.9%   
Avg. net profit/employee Rs Th1,397.9600.0 233.0%   
INCOME DATA
Net Sales Rs m164,666152,193 108.2%  
Other income Rs m1,0203,577 28.5%   
Total revenues Rs m165,686155,769 106.4%   
Gross profit Rs m37,71828,264 133.4%  
Depreciation Rs m5,58013,228 42.2%   
Interest Rs m7771,142 68.0%   
Profit before tax Rs m32,38017,470 185.4%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m8,1832,501 327.2%   
Profit after tax Rs m24,22914,166 171.0%  
Gross profit margin %22.918.6 123.3%  
Effective tax rate %25.314.3 176.5%   
Net profit margin %14.79.3 158.1%  
BALANCE SHEET DATA
Current assets Rs m121,878108,141 112.7%   
Current liabilities Rs m86,80638,322 226.5%   
Net working cap to sales %21.345.9 46.4%  
Current ratio x1.42.8 49.8%  
Inventory Days Days13097 133.9%  
Debtors Days Days6874 91.9%  
Net fixed assets Rs m81,037109,411 74.1%   
Share capital Rs m5861,610 36.4%   
"Free" reserves Rs m116,218140,682 82.6%   
Net worth Rs m116,804142,292 82.1%   
Long term debt Rs m4,51236,621 12.3%   
Total assets Rs m211,052228,606 92.3%  
Interest coverage x42.716.3 261.8%   
Debt to equity ratio x00.3 15.0%  
Sales to assets ratio x0.80.7 117.2%   
Return on assets %11.86.7 176.9%  
Return on equity %20.710.0 208.4%  
Return on capital %27.410.0 274.8%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72751,691 156.2%   
Fx outflow Rs m34,70021,033 165.0%   
Net fx Rs m46,02730,658 150.1%   
CASH FLOW
From Operations Rs m19,54814,628 133.6%  
From Investments Rs m-19,570-8,540 229.1%  
From Financial Activity Rs m8,642-3,855 -224.2%  
Net Cashflow Rs m8,9222,431 367.0%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   VENUS REMEDIES  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 15, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS